These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 21159664)

  • 21. Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma.
    Houghton JA; Cheshire PJ; Hallman JD; Lutz L; Luo X; Li Y; Houghton PJ
    Clin Cancer Res; 1996 Jan; 2(1):107-18. PubMed ID: 9816097
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The sirtuin inhibitor tenovin-6 upregulates death receptor 5 and enhances cytotoxic effects of 5-fluorouracil and oxaliplatin in colon cancer cells.
    Ueno T; Endo S; Saito R; Hirose M; Hirai S; Suzuki H; Yamato K; Hyodo I
    Oncol Res; 2013; 21(3):155-64. PubMed ID: 24512730
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3β and CDK1.
    Mayes PA; Dolloff NG; Daniel CJ; Liu JJ; Hart LS; Kuribayashi K; Allen JE; Jee DI; Dorsey JF; Liu YY; Dicker DT; Brown JM; Furth EE; Klein PS; Sears RC; El-Deiry WS
    Cancer Res; 2011 Aug; 71(15):5265-75. PubMed ID: 21646472
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase.
    Fukushima M; Sakamoto K; Ohshimo H; Nakagawa F; Taguchi T
    Oncol Rep; 2010 Oct; 24(4):835-42. PubMed ID: 20811661
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells.
    Raymond E; Louvet C; Tournigand C; Coudray AM; Faivre S; De Gramont A; Gespach C
    Int J Oncol; 2002 Aug; 21(2):361-7. PubMed ID: 12118332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antitumour activity of XR5944 in vitro and in vivo in combination with 5-fluorouracil and irinotecan in colon cancer cell lines.
    Harris SM; Mistry P; Freathy C; Brown JL; Charlton PA
    Br J Cancer; 2005 Feb; 92(4):722-8. PubMed ID: 15700035
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical antitumor activity of a nanoparticulate SN38.
    Al-Kasspooles MF; Williamson SK; Henry D; Howell J; Niu F; Decedue CJ; Roby KF
    Invest New Drugs; 2013 Aug; 31(4):871-80. PubMed ID: 23299391
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models.
    Troiani T; Napolitano S; Martini G; Martinelli E; Cardone C; Normanno N; Vitagliano D; Morgillo F; Fenizia F; Lambiase M; Formisano L; Bianco R; Ciardiello D; Ciardiello F
    Clin Cancer Res; 2015 Sep; 21(18):4153-64. PubMed ID: 26019172
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ATP citrate lyase mediates resistance of colorectal cancer cells to SN38.
    Zhou Y; Bollu LR; Tozzi F; Ye X; Bhattacharya R; Gao G; Dupre E; Xia L; Lu J; Fan F; Bellister S; Ellis LM; Weihua Z
    Mol Cancer Ther; 2013 Dec; 12(12):2782-91. PubMed ID: 24132143
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pregnane X Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation.
    Raynal C; Pascussi JM; Leguelinel G; Breuker C; Kantar J; Lallemant B; Poujol S; Bonnans C; Joubert D; Hollande F; Lumbroso S; Brouillet JP; Evrard A
    Mol Cancer; 2010 Mar; 9():46. PubMed ID: 20196838
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel lipophilic SN38 prodrug forming stable liposomes for colorectal carcinoma therapy.
    Xing J; Zhang X; Wang Z; Zhang H; Chen P; Zhou G; Sun C; Gu N; Ji M
    Int J Nanomedicine; 2019; 14():5201-5213. PubMed ID: 31371956
    [No Abstract]   [Full Text] [Related]  

  • 32. PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins.
    Zuco V; De Cesare M; Zaffaroni N; Lanzi C; Cassinelli G
    Oncotarget; 2015 Apr; 6(11):8736-49. PubMed ID: 25826089
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan.
    Braun AH; Stark K; Dirsch O; Hilger RA; Seeber S; Vanhoefer U
    Anticancer Drugs; 2005 Nov; 16(10):1099-108. PubMed ID: 16222152
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased p38-MAPK is responsible for chemotherapy resistance in human gastric cancer cells.
    Guo X; Ma N; Wang J; Song J; Bu X; Cheng Y; Sun K; Xiong H; Jiang G; Zhang B; Wu M; Wei L
    BMC Cancer; 2008 Dec; 8():375. PubMed ID: 19091131
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
    Tsavaris N; Ziras N; Kosmas C; Giannakakis T; Gouveris P; Vadiaka M; Dimitrakopoulos A; Karadima D; Rokana S; Papalambros E; Papastratis G; Margaris H; Tsipras H; Polyzos A
    Cancer Chemother Pharmacol; 2003 Dec; 52(6):514-9. PubMed ID: 14504920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Different effects of epigenetic modifiers on the cytotoxicity induced by 5-fluorouracil, irinotecan or oxaliplatin in colon cancer cells.
    Ikehata M; Ogawa M; Yamada Y; Tanaka S; Ueda K; Iwakawa S
    Biol Pharm Bull; 2014; 37(1):67-73. PubMed ID: 24172061
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activation of c-Jun N-terminal kinase (JNK) by widely used specific p38 MAPK inhibitors SB202190 and SB203580: a MLK-3-MKK7-dependent mechanism.
    Muniyappa H; Das KC
    Cell Signal; 2008 Apr; 20(4):675-83. PubMed ID: 18222647
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A systems biology approach identifies SART1 as a novel determinant of both 5-fluorouracil and SN38 drug resistance in colorectal cancer.
    Allen WL; Stevenson L; Coyle VM; Jithesh PV; Proutski I; Carson G; Gordon MA; Lenz HJ; Van Schaeybroeck S; Longley DB; Johnston PG
    Mol Cancer Ther; 2012 Jan; 11(1):119-31. PubMed ID: 22027693
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment.
    Tosi D; Pérez-Gracia E; Atis S; Vié N; Combès E; Gabanou M; Larbouret C; Jarlier M; Mollevi C; Torro A; Del Rio M; Martineau P; Gongora C
    BMC Cancer; 2018 Aug; 18(1):812. PubMed ID: 30103709
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of NF-κB and metastasis in irinotecan (CPT-11)-resistant LoVo colon cancer cells by thymoquinone via JNK and p38.
    Chen MC; Lee NH; Hsu HH; Ho TJ; Tu CC; Chen RJ; Lin YM; Viswanadha VP; Kuo WW; Huang CY
    Environ Toxicol; 2017 Feb; 32(2):669-678. PubMed ID: 27060453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.